{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:15:17Z","timestamp":1774066517996,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["430443\/2018-8"],"award-info":[{"award-number":["430443\/2018-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00210-024-03499-5","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:03:10Z","timestamp":1729594990000},"page":"4211-4218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process"],"prefix":"10.1007","volume":"398","author":[{"given":"Alana Pimentel","family":"Moura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiane Grazieli","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilian","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica Lamberty","family":"Faverzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciele F\u00e1tima","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiano","family":"de Oliveira Poswar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Deon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Regla","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"issue":"5","key":"3499_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D et al (2017) Characterization of classical and nonclassical fabry disease: a multicenter study. J Am Soc Nephrol 28(5):1631\u20131641. https:\/\/doi.org\/10.1681\/ASN.2016090964","journal-title":"J Am Soc Nephrol"},{"key":"3499_CR2","doi-asserted-by":"publisher","unstructured":"Auray-Blais C, Cyr D, Ntwari A et al (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 93(3). https:\/\/doi.org\/10.1016\/j.ymgme.2007.10.001","DOI":"10.1016\/j.ymgme.2007.10.001"},{"issue":"1","key":"3499_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-024-03090-4","volume":"19","author":"L Berry","year":"2024","unstructured":"Berry L, Walter J, Johnson J, Alton J, Powers J, Ll\u00f2ria X, Koulinska I, McGee M, Laney D (2024) Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents. Orphanet J Rare Dis 19(1):153. https:\/\/doi.org\/10.1186\/s13023-024-03090-4","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3499_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB et al (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta (BBA) - Mol Basis Dis 1822(2):226\u2013232. https:\/\/doi.org\/10.1016\/j.bbadis.2011.11.001","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"3499_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"461","author":"GB Biancini","year":"2016","unstructured":"Biancini GB, Jacques CE, Hammerschmidt T et al (2016) Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta 461:41\u201346. https:\/\/doi.org\/10.1016\/j.cca.2016.07.016","journal-title":"Clin Chim Acta"},{"key":"3499_CR6","doi-asserted-by":"publisher","unstructured":"Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of \u03b1-galactosidase a activity and genetic mutations on clinical course. Medicine 81(2). https:\/\/doi.org\/10.1097\/00005792-200203000-00003","DOI":"10.1097\/00005792-200203000-00003"},{"issue":"2","key":"3499_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbrc.2017.03.030","volume":"486","author":"KH Chen","year":"2017","unstructured":"Chen KH, Chou YC, Hsiao CY et al (2017) Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. Biochem Biophys Res Commun 486(2):293\u2013299. https:\/\/doi.org\/10.1016\/j.bbrc.2017.03.030","journal-title":"Biochem Biophys Res Commun"},{"key":"3499_CR8","doi-asserted-by":"publisher","unstructured":"Chen KH, Chien Y, Wang KL et al (2016) Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 32(10). https:\/\/doi.org\/10.1016\/j.cjca.2015.10.033","DOI":"10.1016\/j.cjca.2015.10.033"},{"key":"3499_CR9","doi-asserted-by":"publisher","unstructured":"Cox TM, Cach\u00f3n-Gonz\u00e1lez MB (2012) The cellular pathology of lysosomal diseases. J Pathol 226(2). https:\/\/doi.org\/10.1002\/path.3021","DOI":"10.1002\/path.3021"},{"key":"3499_CR10","doi-asserted-by":"publisher","unstructured":"Curfs JHAJ, Meis JFGM, Hoogkamp-Korstanje JAA (1997) A primer on cytokines: Sources, receptors, effects, and inducers. Clin Microbiol Rev 10(4). https:\/\/doi.org\/10.1128\/cmr.10.4.742","DOI":"10.1128\/cmr.10.4.742"},{"issue":"5","key":"3499_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.bbadis.2015.02.004","volume":"1852","author":"B Donida","year":"2015","unstructured":"Donida B, Marchetti DP, Biancini GB et al (2015) Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta (BBA) - Mol Basis Dis 1852(5):1012\u20131019. https:\/\/doi.org\/10.1016\/j.bbadis.2015.02.004","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"3499_CR12","doi-asserted-by":"publisher","unstructured":"Francesco PN de, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA (2013) Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab 109(1). https:\/\/doi.org\/10.1016\/j.ymgme.2013.02.003","DOI":"10.1016\/j.ymgme.2013.02.003"},{"issue":"5","key":"3499_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"22","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 22(5):30. https:\/\/doi.org\/10.1186\/1750-1172-5-30","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3499_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/MGG3.389","volume":"6","author":"DP Germain","year":"2018","unstructured":"Germain DP, Brand E, Burlina A et al (2018) Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med. 6(4):492\u2013503. https:\/\/doi.org\/10.1002\/MGG3.389","journal-title":"Mol Genet Genomic Med."},{"issue":"2","key":"3499_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/CGE.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S et al (2019) Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 96(2):107\u2013117. https:\/\/doi.org\/10.1111\/CGE.13546","journal-title":"Clin Genet"},{"key":"3499_CR16","doi-asserted-by":"publisher","unstructured":"Gochman E, Mahajna J, Shenzer P et al (2012) The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem 114(8). https:\/\/doi.org\/10.1016\/j.acthis.2012.02.004","DOI":"10.1016\/j.acthis.2012.02.004"},{"key":"3499_CR17","doi-asserted-by":"publisher","unstructured":"Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac, and cerebrovascular outcomes. J Med Genet. Published online December 21, 2022:jmedgenet-2022\u2013108669. https:\/\/doi.org\/10.1136\/JMG-2022-108669","DOI":"10.1136\/JMG-2022-108669"},{"issue":"9","key":"3499_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbadis.2016.05.021","volume":"1862","author":"CED Jacques","year":"2016","unstructured":"Jacques CED, Donida B, Mescka CP et al (2016) Oxidative and nitrative stress and pro-inflammatory cytokines in mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation. Biochim Biophys Acta (BBA) - Mol Basis Dis 1862(9):1608\u20131616. https:\/\/doi.org\/10.1016\/j.bbadis.2016.05.021","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"3499_CR19","doi-asserted-by":"publisher","unstructured":"Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6). https:\/\/doi.org\/10.1101\/cshperspect.a001651","DOI":"10.1101\/cshperspect.a001651"},{"key":"3499_CR20","doi-asserted-by":"publisher","unstructured":"Lee MH, Choi EN, Jeon YJ, Jung SC (2012) Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mol Med 30(6). https:\/\/doi.org\/10.3892\/ijmm.2012.1139","DOI":"10.3892\/ijmm.2012.1139"},{"key":"3499_CR21","doi-asserted-by":"publisher","unstructured":"Levine RL, Garland D, Oliver CN et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186(C). https:\/\/doi.org\/10.1016\/0076-6879(90)86141-H","DOI":"10.1016\/0076-6879(90)86141-H"},{"key":"3499_CR22","doi-asserted-by":"publisher","unstructured":"Lin E, Calvano SE, Lowry SF (2000) Inflammatory cytokines and cell response in surgery. Surgery 127(2). https:\/\/doi.org\/10.1067\/msy.2000.101584","DOI":"10.1067\/msy.2000.101584"},{"key":"3499_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.redox.2014.02.006","volume":"2","author":"HS Marinho","year":"2014","unstructured":"Marinho HS, Real C, Cyrne L, Soares H, Antunes F (2014) Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol 2:535\u2013562. https:\/\/doi.org\/10.1016\/j.redox.2014.02.006","journal-title":"Redox Biol"},{"key":"3499_CR24","doi-asserted-by":"publisher","unstructured":"Mauhin W, Lidove O, Masat E et al (2015) Innate and adaptive immune response in Fabry disease. JIMD Rep 22. https:\/\/doi.org\/10.1007\/8904_2014_371","DOI":"10.1007\/8904_2014_371"},{"key":"3499_CR25","doi-asserted-by":"publisher","unstructured":"Ohkawa H, Ohishi N, Yagi K (1978) Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J Lipid Res 19(8). https:\/\/doi.org\/10.1016\/s0022-2275(20)40690-x","DOI":"10.1016\/s0022-2275(20)40690-x"},{"issue":"4","key":"3499_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/J.YMGME.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ et al (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123(4):416\u2013427. https:\/\/doi.org\/10.1016\/J.YMGME.2018.02.014","journal-title":"Mol Genet Metab"},{"key":"3499_CR27","doi-asserted-by":"publisher","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23(5). https:\/\/doi.org\/10.1093\/ndt\/gfm848","DOI":"10.1093\/ndt\/gfm848"},{"issue":"3","key":"3499_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","volume":"21","author":"L Palaiodimou","year":"2023","unstructured":"Palaiodimou L, Kokotis P, Zompola C, Papagiannopoulou G, Bakola E, Papadopoulou M, Zouvelou V, Petras D, Vlachopoulos C, Tsivgoulis G (2023) Fabry disease: current and novel therapeutic strategies. A Narrative Review. Curr Neuropharmacol 21(3):440\u2013456. https:\/\/doi.org\/10.2174\/1570159X20666220601124117","journal-title":"Curr Neuropharmacol"},{"key":"3499_CR29","doi-asserted-by":"publisher","unstructured":"Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF (2013) Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab 108(4). https:\/\/doi.org\/10.1016\/j.ymgme.2013.01.018","DOI":"10.1016\/j.ymgme.2013.01.018"},{"issue":"11","key":"3499_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/JCM7110409","volume":"7","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Simioni F, Carraro G, Bertoldi G, Pagnin E, Cal\u00f2 LA (2018) Oxidative stress and cardiovascular-renal damage in Fabry disease: is there room for a pathophysiological involvement? J Clin Med 7(11):409. https:\/\/doi.org\/10.3390\/JCM7110409","journal-title":"J Clin Med"},{"issue":"6","key":"3499_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijdevneu.2012.07.002","volume":"30","author":"GS Ribas","year":"2012","unstructured":"Ribas GS, Pires R, Coelho JC et al (2012) Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int J Dev Neurosci 30(6):439\u2013444. https:\/\/doi.org\/10.1016\/j.ijdevneu.2012.07.002","journal-title":"Int J Dev Neurosci"},{"key":"3499_CR32","doi-asserted-by":"publisher","unstructured":"Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA (2009) Anti-inflammatory and pro-inflammatory roles of TGF-\u03b2, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 9(4). https:\/\/doi.org\/10.1016\/j.coph.2009.04.008","DOI":"10.1016\/j.coph.2009.04.008"},{"key":"3499_CR33","doi-asserted-by":"publisher","unstructured":"Shen JS, Meng XL, Moore DF et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95(3). https:\/\/doi.org\/10.1016\/j.ymgme.2008.06.016","DOI":"10.1016\/j.ymgme.2008.06.016"},{"issue":"8","key":"3499_CR34","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/medicina59081478","volume":"59","author":"H Shimohata","year":"2023","unstructured":"Shimohata H, Yamashita M, Yamada K, Hirayama K, Kobayashi M (2023) Treatment of Fabry nephropathy: a literature review. Medicina (Kaunas) 59(8):1478. https:\/\/doi.org\/10.3390\/medicina59081478","journal-title":"Medicina (Kaunas)"},{"key":"3499_CR35","doi-asserted-by":"publisher","unstructured":"Simonaro CM, D\u2019Angelo M, He X et al (2008) Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 172(1). https:\/\/doi.org\/10.2353\/ajpath.2008.070564","DOI":"10.2353\/ajpath.2008.070564"},{"issue":"1","key":"3499_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1172-6-69","volume":"6","author":"BE Smid","year":"2011","unstructured":"Smid BE, Rombach SM, Aerts JM et al (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 6(1):69. https:\/\/doi.org\/10.1186\/1750-1172-6-69","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"3499_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/ATM.2018.11.39","volume":"6","author":"A Sun","year":"2018","unstructured":"Sun A (2018) Lysosomal storage disease overview. Ann Transl Med. 6(24):476\u2013476. https:\/\/doi.org\/10.21037\/ATM.2018.11.39","journal-title":"Ann Transl Med."},{"key":"3499_CR38","doi-asserted-by":"publisher","unstructured":"Thurberg BL, Rennke H, Colvin RB et al (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62(6). https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00675.x","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"3499_CR39","doi-asserted-by":"publisher","unstructured":"T\u00f8ndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51(5). https:\/\/doi.org\/10.1053\/j.ajkd.2007.12.032","DOI":"10.1053\/j.ajkd.2007.12.032"},{"issue":"3","key":"3499_CR40","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3390\/ijms23031887","volume":"23","author":"F Weidemann","year":"2022","unstructured":"Weidemann F, Jovanovic A, Herrmann K, Vardarli I (2022) Chaperone therapy in Fabry disease. Int J Mol Sci 23(3):1887. https:\/\/doi.org\/10.3390\/ijms23031887","journal-title":"Int J Mol Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03499-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03499-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03499-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:01:27Z","timestamp":1744164087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03499-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3499"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03499-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the project was approved by the Research Ethics Committee of the Hospital de Cl\u00ednicas de Porto Alegre (CEP\/HCPA) under number 2018\u20130650. We recruited FD patients who receive care at the ambulatory of Medical Genetics Service in Hospital de Cl\u00ednicas de Porto Alegre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}